# A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers

> **NCT01465139** · PHASE1 · COMPLETED · sponsor: **Celldex Therapeutics** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CDX-301

## Key facts

- **NCT ID:** NCT01465139
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-11
- **Final completion:** 2013-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01465139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01465139, "A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01465139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*